Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


First published on May 15, 2007
A more recent version of this article appeared on July 1, 2007
Neuro Oncol 2007, DOI:10.1215/15228517-2007-003
This Article
Right arrow Advance Publication Full Text (PDF)
Right arrow All Versions of this Article:
9/3/271    most recent
15228517-2007-003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiencke, J. K.
Right arrow Articles by Stokoe, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Copyright 2007 by the Society for Neuro-Oncology

Received June 16, 2006
Accepted October 2, 2006

Basic and Translational Investigations

Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma

John K. Wiencke 1*, Shichun Zheng 1, Nanette Jelluma 2, Tarik Tihan 3, Scott Vandenberg 3, Tanja Tamgüney 4, Rachel Baumber 4, Ramon Parsons 5, Kathleen R. Lamborn 1, Mitchel S. Berger 1, Margaret R. Wrensch 1, Daphne Adele Haas-Kogan 6, David Stokoe 4

1 Department of Neurological Surgery and Brain Tumor Research Center, University of California, San Francisco, San Francisco, CA 94143, USA
2 Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143, USA
3 Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA
4 Cancer Research Institute, University of California, San Francisco, San Francisco, CA 94143, USA
5 Institute of Cancer Genetics, Columbia University, New York, NY, USA
6 Departments of Radiation Oncology, Neurological Surgery and Brain Tumor Research Center, University of California, San Francisco, San Francisco, CA 94143, USA

* To whom correspondence should be addressed. E-mail: John.Wiencke{at}ucsf.edu.


   Abstract

Glioblastoma multiforme (GBM) can present as either de novo or secondary tumors arising from previously diagnosed low-grade gliomas. Although these tumor types are phenotypically indistinguishable, de novo and secondary GBMs are associated with distinct genetic characteristics. PTEN mutations, which result in activation of the phosphoinositide 3-kinase (PI3K) signal transduction pathway, are frequent in de novo but not in secondary GBMs or their antecedent low-grade tumors. Results we present here show that grade II astrocytomas, oligodendrogliomas, and oligoastrocytomas commonly display methylation of the PTEN promoter, a finding that is absent in nontumor brain specimens and rare in de novo GBMs. Methylation of the PTEN promoter correlates with protein kinase B (PKB/Akt) phosphorylation, reflecting functional activation of the PI3K pathway. Our results also demonstrate frequent methylation of the PTEN promoter in grade III astrocytomas and secondary GBMs, consistent with the hypothesis that these tumors arise from lower grade precursors. PTEN methylation is rare in de novo GBMs and is mutually exclusive with PTEN mutations. We conclude that methylation of the PTEN promoter may represent an alternate mechanism by which PI3K signaling is increased in grade II and III gliomas as well as secondary GBMs, a finding that offers new therapeutic approaches in these patients.

Key Words: low-grade glioma, methylation, PKB/Akt, PTEN, secondary glioblastoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Genes Dev.Home page
J. T. Huse, C. Brennan, D. Hambardzumyan, B. Wee, J. Pena, S. H. Rouhanifard, C. Sohn-Lee, C. le Sage, R. Agami, T. Tuschl, et al.
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo
Genes & Dev., June 1, 2009; 23(11): 1327 - 1337.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Hervouet, E. Debien, L. Campion, J. Charbord, J. Menanteau, F. M. Vallette, and P.-F. Cartron
Folate Supplementation Limits the Aggressiveness of Glioma via the Remethylation of DNA Repeats Element and Genes Governing Apoptosis and Proliferation
Clin. Cancer Res., May 15, 2009; 15(10): 3519 - 3529.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Hino, H. Uozaki, N. Murakami, T. Ushiku, A. Shinozaki, S. Ishikawa, T. Morikawa, T. Nakaya, T. Sakatani, K. Takada, et al.
Activation of DNA Methyltransferase 1 by EBV Latent Membrane Protein 2A Leads to Promoter Hypermethylation of PTEN Gene in Gastric Carcinoma
Cancer Res., April 1, 2009; 69(7): 2766 - 2774.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
T. Tamguney and D. Stokoe
New insights into PTEN
J. Cell Sci., December 1, 2007; 120(23): 4071 - 4079.
[Abstract] [Full Text] [PDF]




  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


Copyright 2007 by Society for Neuro-Oncology